中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (9): 1945-1954.doi: 10.4103/1673-5374.335139

• 综述:退行性病与再生 • 上一篇    下一篇

是否有机会在多发性硬化症中使用维生素 D 进行治疗?

  

  • 出版日期:2022-09-15 发布日期:2022-03-05

Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?

Sofia Fernanda Gonçalves Zorzella-Pezavento, Luiza Ayumi Nishiyama Mimura, Marina Bonifácio Denadai, William Danilo Fernandes de Souza, Thais Fernanda de Campos Fraga-Silva, Alexandrina Sartori*   

  1. Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil
  • Online:2022-09-15 Published:2022-03-05
  • Contact: Alexandrina Sartori, PhD, alexandrina.sartori@unesp.br.
  • Supported by:
    This work was supported by the scholarships provided by São Paulo Research Foundation (FAPESP), No. 2013/02371-6 (to LANM), No. 2013/01604-7 ( to SFGZP), No. 2013/14353-2 (to TFCFS), No. 2015/06706-8 (to LANM) and No. 2019/15980-7 (to MBD) and financial support grants No. 2013/26257-8, São Paulo Research Foundation (FAPESP) and No. 307269/2017-5 and the National Council for Scientific and Technological Development (CNPq), to AS.

摘要: Neural Regen Res:维生素 D有望应用于多发性硬化的辅助治疗
多发性硬化是一种自身免疫性可治疗但无法治愈的疾病。治疗多发性硬化的药物种类繁多,主要用于减少疾病复发的次数和严重程度;但并非所有患者都对这些疗法反应良好,并且已经报告其具有严重程度不等的不良反应。
来自巴西圣保罗州立大学的Alexandrina Sartori团队认为,维生素 D 作为多发性硬化辅助疗法的潜在用途值得研究。根据对实验性自身免疫性脑脊髓炎模型的经验以及其他作者在实验模型和临床试验中的大量数据,更早地施用维生素 D可以获得更好的结果。同时维生素 D的无毒剂量、治疗持续时间和在补充维生素 D 期间维持经典治疗的相关性也值得进一步探讨。
文章在《中国神经再生研究(英文版)》杂志2022年9 月9 期发表。

Abstract: Multiple sclerosis is an autoimmune treatable but not curable disease. There are a multiplicity of medications for multiple sclerosis therapy, including a class entitled disease-modifying drugs that are mainly indicated to reduce the number and severity of disease relapses. Not all patients respond well to these therapies, and minor to severe adverse effects have been reported. Vitamin D, called sunshine vitamin, is being studied as a possible light at the end of the tunnel. In this review, we recapitulated the similar immunopathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis, the immunomodulatory and neuroprotective potential of vitamin D and the state-of-art concerning its supplementation to multiple sclerosis patients. Finally, based on our and other groups’ experimental findings, we analyzed the need to consider the relevance of the route and the different time-point administration aspects for a more rational indication of this vitamin to multiple sclerosis patients.

Key words: central nervous system, cytokines, experimental autoimmune encephalomyelitis, immunomodulation, immunopathogenesis, inflammation, multiple sclerosis, neuroprotection, regulatory T cells, vitamin D